Home›Imipramine

Imipramine

25 interactions on record

Imipramine has 25 known drug interactions based on U.S. FDA drug labeling data. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Adrenalin (Epinephrine), Dexmethylphenidate Hydrochloride, Liothyronine Sodium. Patients taking Imipramine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 25
Major: 4
Moderate: 21

Major (4)

Imipramine + Adrenalin (Epinephrine)— Tricyclic antidepressants may potentiate the effects of epinephrine.
Imipramine + Dexmethylphenidate Hydrochloride— Methylphenidate may inhibit the metabolism of imipramine. Downward dose adjustments may be required and plasma drug conc…
Imipramine + Liothyronine Sodium— May increase receptor sensitivity and enhance antidepressant activity; transient cardiac arrhythmias have been observed.…
Imipramine + Norepinephrine Bitartrate— Co-administration can cause severe, prolonged hypertension. Monitor for hypertension if norepinephrine bitartrate cannot…

Moderate (21)

Imipramine + Alprazolam— Steady state plasma concentrations of imipramine can increase by approximately 30% when coadministered with alprazolam u…
Imipramine + Alprazolam Odt C-Iv— Steady state plasma concentrations increase by approximately 30% when administered concomitantly with alprazolam in dose…
Imipramine + Bupropion— CYP2D6 substrate; bupropion inhibits CYP2D6 and increases imipramine concentrations; consider dose reduction.
Imipramine + Bupropion Hcl Er— Bupropion inhibits CYP2D6 and can increase imipramine concentrations; consider dose reduction of imipramine.
Imipramine + Bupropion Hcl Er (Xl)— CYP2D6 substrate antidepressant. Bupropion inhibits CYP2D6, increasing imipramine exposure. Dose reduction may be necess…
Imipramine + Bupropion Hydrobromide— CYP2D6 substrate. Bupropion inhibits CYP2D6 and can increase imipramine concentrations. Consider dose reduction of imipr…
Imipramine + Bupropion Hydrochloride— CYP2D6-metabolized antidepressant. Bupropion inhibits CYP2D6 and can increase imipramine concentrations. Consider dose r…
Imipramine + Dexamethasone Sodium Phosphate, Lidocaine Hydrochloride, Povidine Iodine— Possible interaction with ropivacaine through CYP1A2 competitive inhibition.
Imipramine + Diazepam— CYP2C19 substrate; diazepam may interfere with its metabolism, leading to potential drug-drug interaction.
Imipramine + Dopamine Hydrochloride— Concomitant use may potentiate the cardiovascular effects of dopamine, including hypertension.
Imipramine + Epinephrine— Tricyclic antidepressant that may potentiate the effects of epinephrine.
Imipramine + Iobenguane I-123— Antidepressant that inhibits norepinephrine transporter function, potentially decreasing iobenguane uptake and causing f…
Imipramine + Methylphenidate— Methylphenidate may inhibit metabolism of this tricyclic drug. Downward dose adjustments may be required and plasma conc…
Imipramine + Methylphenidate Hydrochloride— Methylphenidate may inhibit metabolism of imipramine. Downward dosage adjustments may be required.
Imipramine + Nicotine— Smoking cessation with nicotine replacement may require dose decrease due to deinduction of hepatic enzymes.
Imipramine + Paroxetine— Paroxetine is a strong CYP2D6 inhibitor that may increase imipramine concentrations. Use caution and monitor.
Imipramine + Propranolol Hydrochloride— CYP1A2 substrate/inhibitor that may increase blood levels and/or toxicity of propranolol.
Imipramine + Ropivacaine Hydrochloride— Possible interaction via competitive inhibition of CYP1A2 metabolism; caution advised.
Imipramine + Zaleplon— Co-administration produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours…
Imipramine + Zolpidem Tartrate— Additive effect of decreased alertness observed. No pharmacokinetic interaction except 20% decrease in imipramine peak l…
Imipramine + Zolpidem Tartrate Sublingual— Additive effect of decreased alertness observed. 20% decrease in peak levels of imipramine with no other pharmacokinetic…

Imipramine + Adrenalin (Epinephrine)⚠️Major

Tricyclic antidepressants may potentiate the effects of epinephrine.

Imipramine + Dexmethylphenidate Hydrochloride⚠️Major

Methylphenidate may inhibit the metabolism of imipramine. Downward dose adjustments may be required and plasma drug concentration should be monitored.

Imipramine + Liothyronine Sodium⚠️Major

May increase receptor sensitivity and enhance antidepressant activity; transient cardiac arrhythmias have been observed. Thyroid hormone activity may also be enhanced.

Imipramine + Norepinephrine Bitartrate⚠️Major

Co-administration can cause severe, prolonged hypertension. Monitor for hypertension if norepinephrine bitartrate cannot be avoided.

Imipramine + Alprazolam🟡Moderate

Steady state plasma concentrations of imipramine can increase by approximately 30% when coadministered with alprazolam up to 4 mg/day. Clinical significance unknown.

Imipramine + Alprazolam Odt C-Iv🟡Moderate

Steady state plasma concentrations increase by approximately 30% when administered concomitantly with alprazolam in doses up to 4 mg/day. Clinical significance unknown.

Imipramine + Bupropion🟡Moderate

CYP2D6 substrate; bupropion inhibits CYP2D6 and increases imipramine concentrations; consider dose reduction.

Imipramine + Bupropion Hcl Er🟡Moderate

Bupropion inhibits CYP2D6 and can increase imipramine concentrations; consider dose reduction of imipramine.

Imipramine + Bupropion Hcl Er (Xl)🟡Moderate

CYP2D6 substrate antidepressant. Bupropion inhibits CYP2D6, increasing imipramine exposure. Dose reduction may be necessary.

Imipramine + Bupropion Hydrobromide🟡Moderate

CYP2D6 substrate. Bupropion inhibits CYP2D6 and can increase imipramine concentrations. Consider dose reduction of imipramine when used with bupropion.

Imipramine + Bupropion Hydrochloride🟡Moderate

CYP2D6-metabolized antidepressant. Bupropion inhibits CYP2D6 and can increase imipramine concentrations. Consider dose reduction.

Imipramine + Dexamethasone Sodium Phosphate, Lidocaine Hydrochloride, Povidine Iodine🟡Moderate

Possible interaction with ropivacaine through CYP1A2 competitive inhibition.

Imipramine + Diazepam🟡Moderate

CYP2C19 substrate; diazepam may interfere with its metabolism, leading to potential drug-drug interaction.

Imipramine + Dopamine Hydrochloride🟡Moderate

Concomitant use may potentiate the cardiovascular effects of dopamine, including hypertension.

Imipramine + Epinephrine🟡Moderate

Tricyclic antidepressant that may potentiate the effects of epinephrine.

Imipramine + Iobenguane I-123🟡Moderate

Antidepressant that inhibits norepinephrine transporter function, potentially decreasing iobenguane uptake and causing false negative imaging results.

Imipramine + Methylphenidate🟡Moderate

Methylphenidate may inhibit metabolism of this tricyclic drug. Downward dose adjustments may be required and plasma concentrations should be monitored.

Imipramine + Methylphenidate Hydrochloride🟡Moderate

Methylphenidate may inhibit metabolism of imipramine. Downward dosage adjustments may be required.

Imipramine + Nicotine🟡Moderate

Smoking cessation with nicotine replacement may require dose decrease due to deinduction of hepatic enzymes.

Imipramine + Paroxetine🟡Moderate

Paroxetine is a strong CYP2D6 inhibitor that may increase imipramine concentrations. Use caution and monitor.

Imipramine + Propranolol Hydrochloride🟡Moderate

CYP1A2 substrate/inhibitor that may increase blood levels and/or toxicity of propranolol.

Imipramine + Ropivacaine Hydrochloride🟡Moderate

Possible interaction via competitive inhibition of CYP1A2 metabolism; caution advised.

Imipramine + Zaleplon🟡Moderate

Co-administration produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours. Pharmacodynamic interaction with no alteration of either drug's pharmacokinetics.

Imipramine + Zolpidem Tartrate🟡Moderate

Additive effect of decreased alertness observed. No pharmacokinetic interaction except 20% decrease in imipramine peak levels.

Imipramine + Zolpidem Tartrate Sublingual🟡Moderate

Additive effect of decreased alertness observed. 20% decrease in peak levels of imipramine with no other pharmacokinetic interaction.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.